
AICURA medical is a data and AI company revolutionizing clinical drug development by providing a secure, collaborative data ecosystem that accelerates clinical research and improves patient outcomes. Their platform integrates multimodal clinical data with pre-trained AI models, enabling scalable deployment across therapeutic areas, particularly neurodegenerative diseases. The platform supports data aggregation, exploration, curation, and AI-driven predictive modeling, facilitating biomarker discovery, patient cohort enrichment, and trial feasibility studies. AICURA's technology reduces costs and resource demands, de-risks drug development, and enhances clinical trial efficiency. Founded in 2018 and based in Berlin, the company collaborates with biotech firms, healthcare providers, medtech companies, and academic institutions, having secured over €3.5 million in research funding and established a strong presence in clinical research for neurodegenerative disorders.

AICURA medical is a data and AI company revolutionizing clinical drug development by providing a secure, collaborative data ecosystem that accelerates clinical research and improves patient outcomes. Their platform integrates multimodal clinical data with pre-trained AI models, enabling scalable deployment across therapeutic areas, particularly neurodegenerative diseases. The platform supports data aggregation, exploration, curation, and AI-driven predictive modeling, facilitating biomarker discovery, patient cohort enrichment, and trial feasibility studies. AICURA's technology reduces costs and resource demands, de-risks drug development, and enhances clinical trial efficiency. Founded in 2018 and based in Berlin, the company collaborates with biotech firms, healthcare providers, medtech companies, and academic institutions, having secured over €3.5 million in research funding and established a strong presence in clinical research for neurodegenerative disorders.
Founded: 2018 (Berlin)
Product: Multimodal data + AI platform for clinical research
Focus: Neurodegenerative diseases and biomarker discovery
Team size (reported): 16 employees
Known funding: Seed activity through 2019; accelerator support from SpinLab
Clinical drug development and clinical research for neurodegenerative disorders (e.g., Alzheimer’s, dementia).
2018
Biotechnology
Last reported round dated Dec 2019; multiple early-stage funding events reported between 2018 and 2019.
Reported early funding event (Mar 2019) per public profiles.
Reported early funding event (Sep 2018) per public profiles.
“SpinLab - The HHL Accelerator (non-equity/accelerator support)”